Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Benzinga Newsdesk www.benzinga.com Positive 88.2%

Neg 0% Neu 0% Pos 88.2%

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.